Patents by Inventor Nicole Rouquet

Nicole Rouquet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11839648
    Abstract: The invention relates to an autologous cancer vaccine and also to the method for producing same comprising the following steps: a) extracting the proteins contained in a serum or plasma sample obtained from a patient suffering from cancer; and b) bringing the proteins extracted in step a) into contact with particles of hydroxyapatite and/or tricalcium phosphate.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: December 12, 2023
    Assignee: HASTIM
    Inventors: Patrick Frayssinet, Nicole Rouquet
  • Patent number: 11338034
    Abstract: The present invention relates to a hydroxyapatite and/or tricalcium phosphate powder characterized in that it has undergone at least one sintering step at a temperature between 400° C. and 600° C. The invention also relates to a process for preparing such a powder, and to a composition comprising such a powder for use as an anti-tumour auto-vaccine and particularly in the treatment of the following pathological conditions: osteosarcoma, B or T lymphoma, mammary tumour, melanoma, haemangiosarcoma, mastocytoma, fibrosarcoma, brain tumours and schwannoma in a subject. The present invention also covers a drug combination comprising the composition of the invention and at least one second therapeutic agent, preferably an anti-tumour agent and/or a radiotherapeutic agent.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: May 24, 2022
    Assignee: URODELIA
    Inventors: Nicole Rouquet, Patrick Frayssinet
  • Publication number: 20210308259
    Abstract: The present invention relates to a hydroxyapatite and/or tricalcium phosphate powder characterized in that it has undergone at least one sintering step at a temperature between 400° C. and 600° C. The invention also relates to a process for preparing such a powder, and to a composition comprising such a powder for use as an anti-tumour auto-vaccine and particularly in the treatment of the following pathological conditions: osteosarcoma, B or T lymphoma, mammary tumour, melanoma, haemangiosarcoma, mastocytoma, fibrosarcoma, brain tumours and schwannoma in a subject. The present invention also covers a drug combination comprising the composition of the invention and at least one second therapeutic agent, preferably an anti-tumour agent and/or a radiotherapeutic agent.
    Type: Application
    Filed: March 4, 2014
    Publication date: October 7, 2021
    Inventors: Nicole Rouquet, Patrick Frayssinet
  • Publication number: 20210008187
    Abstract: The invention relates to an autologous cancer vaccine and also to the method for producing same comprising the following steps: a) extracting the proteins contained in a serum or plasma sample obtained from a patient suffering from cancer; and b) bringing the proteins extracted in step a) into contact with particles of hydroxyapatite and/or tricalcium phosphate.
    Type: Application
    Filed: March 13, 2019
    Publication date: January 14, 2021
    Applicant: Urodelia
    Inventors: Patrick FRAYSSINET, Nicole ROUQUET
  • Patent number: 9326942
    Abstract: The invention relates to a medicament characterized in that it comprises at least one solid biocompatible support, preferably in powder form, on which at least one active substance, preferably selected among biological materials and/or biological molecules, is adsorbed or on which it is to be adsorbed, preferably without requiring a coupling agent. Said solid biocompatible support is capable of purifying the active substance. The invention relates to also relates to a method for preparing a medicament of the aforementioned type, this method essentially consisting of placing at least one solid biocompatible support, preferably in powder form, in contact with at least one active substance, preferably selected among biological materials and/or biological molecules, in such a manner that the active substance is reversibly adsorbed and without denaturing on the support.
    Type: Grant
    Filed: May 15, 2006
    Date of Patent: May 3, 2016
    Assignee: URODELIA
    Inventors: Daniel Ciocca, Patrick Frayssinet, Nicole Rouquet
  • Publication number: 20090214585
    Abstract: The invention relates to a medicament characterized in that it comprises at least one solid biocompatible support, preferably in powder form, on which at least one active substance, preferably selected among biological materials and/or biological molecules, is adsorbed or on which it is to be adsorbed, preferably without requiring a coupling agent. Said solid biocompatible support is capable of purifying the active substance. The invention relates to also relates to a method for preparing a medicament of the aforementioned type, this method essentially consisting of placing at least one solid biocompatible support, preferably in powder form, in contact with at least one active substance, preferably selected among biological materials and/or biological molecules, in such a manner that the active substance is reversibly adsorbed and without denaturing on the support.
    Type: Application
    Filed: May 15, 2006
    Publication date: August 27, 2009
    Applicants: URODELIA
    Inventors: Daniel Ciocca, Patrick Frayssinet, Nicole Rouquet
  • Publication number: 20070048737
    Abstract: The invention relates to a method of modifying the surface of calcium phosphate ceramics and powders. The inventive method involves maturation in a culture medium, thereby causing epitaxial carbonated apatite growth at the surface of the aforementioned ceramics and powders. The invention also relates to the use of said modified ceramics and powders for in vitro and in vivo cell transfection and for cell culture in a three-dimensional network.
    Type: Application
    Filed: December 24, 2003
    Publication date: March 1, 2007
    Inventors: Nicole Rouquet, Patrick Pierre Frayssinet
  • Publication number: 20070041908
    Abstract: The invention relates to a degradable, biocompatible material which is made from a phosphocalcic cement comprising magnetic particles. Said material can be used to treat bone metastases by means of thermolysis and/or to mark cancer cells.
    Type: Application
    Filed: July 7, 2004
    Publication date: February 22, 2007
    Inventors: Patrick Frayssinet, Nicole Rouquet